Spyre Therapeutics, Inc.: Form 10-Q for the period ended Sep 30, 2022
Filed with the SEC on Nov 3, 2022 and accepted by EDGAR at Nov 3, 2022, 07:05 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2022-09-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2022-07-01 to 2022-09-30 | $174.0k | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 9 months2022-01-01 to 2022-09-30 | $2.2m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Research and development | 3 months2022-07-01 to 2022-09-30 | $12.0m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months2022-01-01 to 2022-09-30 | $44.3m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2022-07-01 to 2022-09-30 | −$18.8m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2022-01-01 to 2022-09-30 | −$65.6m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months2022-07-01 to 2022-09-30 | −$209.0k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months2022-01-01 to 2022-09-30 | −$174.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2022-07-01 to 2022-09-30 | −$18.2m | us-gaap:NetIncomeLoss |
| Net income | 9 months2022-01-01 to 2022-09-30 | −$65.0m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2022-07-01 to 2022-09-30 | −$0.19 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months2022-01-01 to 2022-09-30 | −$0.81 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2022-07-01 to 2022-09-30 | −$0.19 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months2022-01-01 to 2022-09-30 | −$0.81 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2022-07-01 to 2022-09-30 | 94,197,958 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months2022-01-01 to 2022-09-30 | 80,574,683 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months2022-01-01 to 2022-09-30 | −$62.0m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months2022-01-01 to 2022-09-30 | $38.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2022-09-30 | $39.0m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2022-09-30 | $82.2m | us-gaap:AssetsCurrent |
| Total assets | At period end2022-09-30 | $91.6m | us-gaap:Assets |
| Current liabilities | At period end2022-09-30 | $17.7m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2022-09-30 | $24.0m | us-gaap:Liabilities |
| Shareholders' equity | At period end2022-09-30 | $67.6m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0000950170-22-021529. Last ingested by Listed: Nov 3, 2026, 18:46 ET. Listed shows no prices and gives no investment advice.